169 related articles for article (PubMed ID: 31290003)
41. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis.
Guo T; Liu P; Yang J; Wu P; Chen B; Liu Z; Li Z
J Cancer; 2019; 10(19):4671-4678. PubMed ID: 31528232
[No Abstract] [Full Text] [Related]
43. A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China.
Zhang JY; Dai M; Wang X; Lu WQ; Li DS; Zhang MX; Wang KJ; Dai LP; Han SG; Zhou YF; Zhuang H
Int J Epidemiol; 1998 Aug; 27(4):574-8. PubMed ID: 9758109
[TBL] [Abstract][Full Text] [Related]
44. Hepatitis C Virus Mediated Metastasis in Hepatocellular Carcinoma as a Therapeutic Target for Cancer Management.
Khera L; Paul C; Kaul R
Curr Drug Metab; 2018; 19(3):224-235. PubMed ID: 29380693
[TBL] [Abstract][Full Text] [Related]
45. Nonsurgical management of advanced hepatocellular carcinoma: a clinical practice guideline.
Meyers BM; Knox J; Cosby R; Beecroft JR; Chan KKW; Coburn N; Feld J; Jonker D; Mahmud A; Ringash J;
Curr Oncol; 2020 Apr; 27(2):e106-e114. PubMed ID: 32489260
[TBL] [Abstract][Full Text] [Related]
46. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
[TBL] [Abstract][Full Text] [Related]
47. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis.
Zhuang L; Zeng X; Yang Z; Meng Z
PLoS One; 2013; 8(9):e61361. PubMed ID: 24069133
[TBL] [Abstract][Full Text] [Related]
48. Changing relative roles of hepatitis B and C viruses in the aetiology of hepatocellular carcinoma in Greece. Epidemiological and clinical observations.
Raptis I; Koskinas J; Emmanouil T; Hadziyannis S
J Viral Hepat; 2003 Nov; 10(6):450-4. PubMed ID: 14633179
[TBL] [Abstract][Full Text] [Related]
49. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan.
Shiratori Y; Shiina S; Imamura M; Kato N; Kanai F; Okudaira T; Teratani T; Tohgo G; Toda N; Ohashi M
Hepatology; 1995 Oct; 22(4 Pt 1):1027-33. PubMed ID: 7557847
[TBL] [Abstract][Full Text] [Related]
50. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.
Zondervan PE; Wink J; Alers JC; IJzermans JN; Schalm SW; de Man RA; van Dekken H
J Pathol; 2000 Oct; 192(2):207-15. PubMed ID: 11004697
[TBL] [Abstract][Full Text] [Related]
51. Hepatitis B virus mutation may play a role in hepatocellular carcinoma recurrence: A systematic review and meta-regression analysis.
Zhou HY; Luo Y; Chen WD; Gong GZ
J Gastroenterol Hepatol; 2015 Jun; 30(6):977-83. PubMed ID: 25689418
[TBL] [Abstract][Full Text] [Related]
52. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
[TBL] [Abstract][Full Text] [Related]
53. Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature.
Atkin C; Earwaker P; Pallan A; Shetty S; Punia P; Ma YT
BMC Gastroenterol; 2017 Feb; 17(1):30. PubMed ID: 28193171
[TBL] [Abstract][Full Text] [Related]
54. [Clinical research progression of molecular-targeted drugs and PD-1 inhibitors for advanced hepatocellular carcinoma].
Lai JM; Hu S; Lin H; Luo H; Luo YB
Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):406-409. PubMed ID: 31216824
[TBL] [Abstract][Full Text] [Related]
55. Minor role of hepatitis B and C virus infection in the etiology of hepatocellular carcinoma in a low-endemic area.
Kaczynski J; Hansson G; Hermodsson S; Olsson R; Wallerstedt S
Scand J Gastroenterol; 1996 Aug; 31(8):809-13. PubMed ID: 8858752
[TBL] [Abstract][Full Text] [Related]
56. Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis.
Manthravadi S; Paleti S; Pandya P
Int J Cancer; 2017 Mar; 140(5):1042-1049. PubMed ID: 27861842
[TBL] [Abstract][Full Text] [Related]
57. Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials.
Zhang CH; Xu GL; Jia WD; Li JS; Ma JL; Ge YS
Int J Cancer; 2011 Sep; 129(5):1254-64. PubMed ID: 21710498
[TBL] [Abstract][Full Text] [Related]
58. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.
Raoul JL; Kudo M; Finn RS; Edeline J; Reig M; Galle PR
Cancer Treat Rev; 2018 Jul; 68():16-24. PubMed ID: 29783126
[TBL] [Abstract][Full Text] [Related]
59. Non-Invasive Diagnostic Criteria for Hepatocellular Carcinoma in Hepatitis B Virus-Endemic Areas: Is Cirrhosis Indispensable?
Huang XW; Liao B; Huang Y; Liang JY; Shan QY; Shen SL; Xie XY; Lu MD; Chen LD; Wang W
Dig Dis; 2018; 36(3):228-235. PubMed ID: 29353268
[TBL] [Abstract][Full Text] [Related]
60. Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis.
Vogel A; Rimassa L; Sun HC; Abou-Alfa GK; El-Khoueiry A; Pinato DJ; Sanchez Alvarez J; Daigl M; Orfanos P; Leibfried M; Blanchet Zumofen MH; Gaillard VE; Merle P
Liver Cancer; 2021 Jun; 10(3):240-248. PubMed ID: 34239810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
